All In Biotech

Drug Trial Radar · NCT04270760

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 281 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

281

Actual

Start

Jul 28, 2020

Primary completion

Dec 27, 2021

Study completion Nov 8, 2022

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).

Conditions

  • Cardiovascular Disease

Interventions

  • OlpasiranDrug

    Dose 1 Dose 2 Dose 3 Dose 4

  • PlaceboDrug

    Dose 5

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36Time frame: Baseline and Week 36

Locations

36 sites in 7 countries. Site status is shown where the registry gives one.

  • Westside Medical Associates of Los Angeles

    Beverly Hills, California

  • Excel Medical Clinical Trials

    Boca Raton, Florida

  • Piedmont Healthcare

    Atlanta, Georgia

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Johns Hopkins

    Baltimore, Maryland

  • New York University

    New York, New York

  • Mount Sinai Hospital

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Crossroads Clinical Research Inc

    Mooresville, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Baylor College of Medicine

    Houston, Texas

  • Protenium Clinical Research

    Hurst, Texas

  • Dr Heart Pty Ltd

    Woolloongabba, Australia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Core Research Group Pty Ltd

    Milton, Queensland, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Linear Clinical Research Limited

    Nedlands, Western Australia, Australia

  • LMC Clinical Research Incorporated

    Brampton, Ontario, Canada

  • LMC Clinical Research Incorporated Thornhill

    Concord, Ontario, Canada

  • Ecogene-21

    Chicoutimi, Quebec, Canada

  • Research Institute of McGill University Health Center - Glen Site

    Montreal, Quebec, Canada

  • Clinique des Maladies Lipidiques de Quebec Incorporated

    Québec, Quebec, Canada

  • Aarhus Universitetshospital

    Aarhus N, Denmark

  • Herlev Gentofte Hospital

    Herlev, Denmark

  • Regionshospitalet Viborg

    Viborg, Denmark

  • Thjonustumidstod Rannsoknaverkefna

    Kopavogur, Iceland

  • Asahi General Hospital

    Asahi-shi, Chiba, Japan

  • The Jikei University Kashiwa Hospital

    Kashiwa-shi, Chiba, Japan

  • Asahikawa City Hospital

    Asahikawa-shi, Hokkaido, Japan

  • Kanazawa Medical University Hospital

    Kahoku-gun, Ishikawa-ken, Japan

  • Saitama Medical University Hospital

    Iruma-gun, Saitama, Japan

  • Academisch Medisch Centrum

    Amsterdam, Netherlands

  • Rijnstate Ziekenhuis

    Arnhem, Netherlands

  • Haga Ziekenhuis

    The Hague, Netherlands

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • VieCuri Medisch Centrum

    Venlo, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.